Skip to content

Speaker’s Bureau: Janssen Psoriasis (Ustekinumab, infliximab, golimumab)

Speaker’s Bureau: Janssen Psoriasis (Ustekinumab, infliximab, golimumab); Psoriasis is a common chronic skin disorder typically characterized by erythematous papules and plaques with a silver scale, although other presentations occur. BioTRAC is an ongoing Canadian prospective, multicentre, observational registry collecting real-world clinical, laboratory, patient-centric and safety data in RA, ankylosing spondylitis and psoriatic arthritis patients treated with infliximab, golimumab or ustekinumab as part of their routine care.

Speaker's Bureau: Janssen Psoriasis (Ustekinumab, infliximab, golimumab) 2Psoriatic Arthritis Long-term Assessment of Clinical Efficacy 1 (PALACE 1) compared apremilast with placebo in patients with active psoriatic arthritis despite prior. PJM has received research grants and consultant fees from and served on the speaker’s bureau for Abbott, Amgen, Biogen Idec, BMS, Genentech, Janssen, Eli Lilly, Pfizer and UCB, and received research grants and consultant fees from Celgene Corporation, Novartis and Roche. Infliximab is the most common cause of urticarial reactions in rheumatoid arthritis (RA) patients, with an estimated frequency of 4. In contrast, there has been a reported case of an eczematous drug eruption in a psoriasis patient following treatment with ustekinumab, the approved anti-IL-12/23 monoclonal antibody. Disclosures: Dr. Strober is with the speakers bureau for AbbVie; consultant for AbbVie, Amgen, Celgene, Novartis, Merck, Lilly, Pfizer, Janssen and Maruho; investigator for AbbVie, Amgen, Novartis, Lilly and Janssen. Strober is with the speakers bureau for AbbVie; consultant for AbbVie, Amgen, Celgene, Novartis, Merck, Lilly, Pfizer, Janssen and Maruho; investigator for AbbVie, Amgen, Novartis, Lilly and Janssen. Speaker’s Bureau: MSD Spondyloarthritis (Infliximab, Golimumab).

Served as a speaker or a member of a speakers bureau for: AbbVie Inc.; Crescendo Bioscience; Genentech, Inc.; Janssen Pharmaceuticals Products, L.P.; A Menter receives grant/research support from AbbVie, Allergan, Amgen, APoPharma, Boehringer Ingelheim, Cengene, Convoy Therapeutics, Eli Lilly and Company, Genentech, Janssen Biotech, Leo Pharma, Merck, Novartis, Pfizer, Symbio, Syntrix, Wyeth, and XenoPort; is a consultant of AbbVie, Allergan, Amgen, Convoy Therapeutics, Eli Lilly and Company, Janssen Biotech, Novartis, Pfizer, Syntrix, Wyeth, and Xenoport; and is a member of the speakers bureau of AbbVie, Amgen, Janssen Biotech, Leo Pharma, and Wyeth. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. Has received research support from BMS, MSD and Roche, and has acted as a consultant and is a member of the speakers’ bureau for Abbvie, BMS, Janssen, Medac, MSD, Pfizer and Roche.

Extended Report: Treatment Of Psoriatic Arthritis In A Phase 3 Randomised, Placebo-controlled Trial With Apremilast, An Oral Phosphodiesterase 4 Inhibitor

Speaker's Bureau: Janssen Psoriasis (Ustekinumab, infliximab, golimumab) 3The more recently developed TNFi agents golimumab and certolizumab pegol have also been shown effective in the treatment of PsA 40, 41. DJV received unrestricted educational funding from Abbvie, Actelion, MSD, Opsona, Pfizer, Roche and UCB; is on the speaker bureau for Actelion, MSD, Pfizer, Janssen, and UCB; and is advisor to Abbvie, Actelion, MSD, Pfizer, Roche and UCB. Through More Than Skin Deep, Triggers, Treatments and You learn what triggers your disease and how treatments fight your psoriasis and psoriatic arthritis sy. Inc., Janssen Biotech, UV BioTek, LLC Speaker’s Bureau: AbbVie, Inc. AbbVie -Remicade (Infliximab) – Janssen -Simponi (Golimumab) – Janssen -Cimzia (Certolizumab) – UCB. Psoriatic arthritis (PsA) is the second most common inflammatory arthropathy, after rheumatoid arthritis diagnosis, in early arthritis clinics. The more recently developed TNFi agents golimumab and certolizumab pegol have also been shown effective in the treatment of PsA 40, 41. DJV received unrestricted educational funding from Abbvie, Actelion, MSD, Opsona, Pfizer, Roche and UCB; is on the speaker bureau for Actelion, MSD, Pfizer, Janssen, and UCB; and is advisor to Abbvie, Actelion, MSD, Pfizer, Roche and UCB.

Psoriatic Arthritis: Recent Progress In Pathophysiology And Drug Development